Forbes November 27, 2020
The past few weeks have been sort of like first dates with three different Covid-19 coronavirus vaccines. They were positive first dates, but first dates nonetheless.
Since November 9, three vaccine manufacturers, Pfizer, followed by Moderna and then AstraZeneca, have offered some preliminary results from their Phase 3 clinical trials. And those numbers have looked good. Pfizer mentioned a vaccine efficacy of above 90% for its mRNA-based vaccine candidate, BNT162b2, Moderna a vaccine efficacy of 94.5% for its mRNA-1273, and AstraZeneca a vaccine efficacy of up to 90% for its AZD1222.
Ninety percent is an impressive number. However, before you say, “you had me at 90%,” keep in mind that these are still very preliminary results. Don’t start dreaming about...